Perspective Therapeutics, Inc. (CATX) 10-Year Financial Performance & Capital Metrics

CATX • • Industrial / General

HealthcareMedical DevicesOncology & Cancer Treatment DevicesRadiation Therapy Systems

AboutPerspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.Show more

Revenue $0 -100.0%
EBITDA $10M +126.2%
Net Income -$79M -70.5%
EPS (Diluted) -1.23 -44.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -43.34% +39.5%
ROIC 5.2% +108.7%
Debt/Equity 0.01 -58.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 17.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-74.35%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-92.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM-49.38%

ROCE

10Y Avg-40.23%

5Y Avg-26.06%

3Y Avg-26.49%

Latest5.16%

Peer Comparison

Radiation Therapy Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
SRTSSensus Healthcare, Inc.	81.47M	4.96	12.10	71.31%	-8.44%	-5.87%	0.01
CATXPerspective Therapeutics, Inc.	184.36M	2.48	-2.02	-100%	-197.29%	-42.77%	0.01
TLSITriSalus Life Sciences, Inc.	307.28M	6.15	-4.92	58.99%	-98.45%
PROFProfound Medical Corp.	302.68M	8.34	-7.79	41.23%	-272.77%	-130.59%	0.08
DCTHDelcath Systems, Inc.	354.29M	10.21	-11.03	17.02%	1.5%	1.04%	0.02
PTHLPheton Holdings Ltd Class A Ordinary Shares	8.46M	0.90	-17.38	-28.7%	-91.16%	-13.91%	0.04
ARAYAccuray Incorporated	98.61M	0.87	-56.13	2.68%	-4.28%	-31.22%	2.17

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.77M	4.76M	5.92M	7.31M	9.68M	10.05M	10.79M	7.1M	1.43M	0
Revenue Growth %	0.04%	-0%	0.24%	0.23%	0.32%	0.04%	0.07%	-0.34%	-0.8%	-1%
Cost of Goods Sold+	4.64M	3.92M	4.08M	4.27M	4.56M	4.93M	6.18M	5.47M	0	0
COGS % of Revenue	0.97%	0.82%	0.69%	0.58%	0.47%	0.49%	0.57%	0.77%	-	-
Gross Profit+	129.15K	838K	1.84M	3.05M	5.12M	5.12M	4.62M	1.63M	1.43M	0
Gross Margin %	0.03%	0.18%	0.31%	0.42%	0.53%	0.51%	0.43%	0.23%	1%	-
Gross Profit Growth %	-0.23%	5.49%	1.2%	0.65%	0.68%	-0%	-0.1%	-0.65%	-0.12%	-1%
Operating Expenses+	5.21M	7.14M	8.57M	8.32M	8.6M	8.56M	12.01M	17.43M	42.38M	92.34M
OpEx % of Revenue	1.09%	1.5%	1.45%	1.14%	0.89%	0.85%	1.11%	2.45%	29.55%	-
Selling, General & Admin	5.14M	6.23M	6.83M	6.85M	7.55M	7.13M	9.43M	14.21M	21.06M	26.61M
SG&A % of Revenue	1.08%	1.31%	1.15%	0.94%	0.78%	0.71%	0.87%	2%	14.69%	-
Research & Development	528.05K	965K	1.75M	1.47M	1.13M	1.43M	2.58M	2.6M	21.31M	41.64M
R&D % of Revenue	0.11%	0.2%	0.29%	0.2%	0.12%	0.14%	0.24%	0.37%	14.86%	-
Other Operating Expenses	-456.28K	-48K	0	2K	-73K	0	0	0	0	24.09M
Operating Income+	-5.08M	-6.31M	-6.73M	-5.28M	-3.48M	-3.44M	-7.39M	-15.18M	-40.94M	10.46M
Operating Margin %	-1.07%	-1.32%	-1.14%	-0.72%	-0.36%	-0.34%	-0.68%	-2.14%	-28.55%	-
Operating Income Growth %	-0.17%	-0.24%	-0.07%	0.22%	0.34%	0.01%	-1.15%	-1.05%	-1.7%	1.26%
EBITDA+	-4.61M	-6.24M	-6.65M	-5.3M	-3.33M	-3.43M	-7.14M	-14.84M	-39.96M	10.46M
EBITDA Margin %	-0.97%	-1.31%	-1.12%	-0.72%	-0.34%	-0.34%	-0.66%	-2.09%	-27.87%	-
EBITDA Growth %	-0.23%	-0.35%	-0.07%	0.2%	0.37%	-0.03%	-1.08%	-1.08%	-1.69%	1.26%
D&A (Non-Cash Add-back)	470.85K	68K	80K	-24K	147K	9K	248K	344K	981K	0
EBIT	0	-6.31M	-6.73M	-5.28M	0	-3.44M	0	-15.18M	-40.94M	-81.42M
Net Interest Income+	217K	118K	29K	108K	30K	59K	0	1.12M	850K	10.56M
Interest Income	218K	118K	29K	108K	30K	59K	119K	1.12M	934K	10.52M
Interest Expense	1K	0	0	0	0	0	119K	0	84K	-48K
Other Income/Expense	154K	27K	29K	134K	30K	50K	119K	512K	835K	-91.83M
Pretax Income+	-4.71M	-6.16M	-6.7M	-5.14M	-3.45M	-3.39M	-7.27M	-14.67M	-40.11M	-81.38M
Pretax Margin %	-0.99%	-1.29%	-1.13%	-0.7%	-0.36%	-0.34%	-0.67%	-2.07%	-27.97%	-
Income Tax+	-371.19K	-145K	-29K	-294K	-177K	-199K	-119K	0	-2.65M	-2.1M
Effective Tax Rate %	1%	1%	1%	0.94%	0.95%	0.94%	0.98%	1%	1.16%	0.97%
Net Income+	-4.71M	-6.16M	-6.7M	-4.85M	-3.27M	-3.19M	-7.15M	-14.67M	-46.51M	-79.28M
Net Margin %	-0.99%	-1.29%	-1.13%	-0.66%	-0.34%	-0.32%	-0.66%	-2.07%	-32.43%	-
Net Income Growth %	-0.28%	-0.31%	-0.09%	0.28%	0.33%	0.02%	-1.24%	-1.05%	-2.17%	-0.7%
Net Income (Continuing)	-	-	-	-4.85M	-3.27M	-3.19M	-7.15M	-14.67M	-37.45M	-80.43M
Discontinued Operations	0	0	0	0	0	0	0	0	-9.05M	-949K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.09	-0.11	-0.12	-0.07	-0.05	-0.06	-0.13	-0.27	-0.85	-1.23
EPS Growth %	-0.28%	-0.29%	-0.09%	0.4%	0.33%	-0.2%	-1.24%	-1.08%	-2.15%	-0.45%
EPS (Basic)	-0.09	-0.11	-0.12	-0.07	-0.05	-0.06	-0.13	-0.27	-0.85	-1.23
Diluted Shares Outstanding	55.02M	55.02M	55.16M	67.04M	67.6M	54.91M	54.91M	54.91M	54.91M	64.42M
Basic Shares Outstanding	55.01M	55.02M	55.16M	67.04M	67.6M	54.91M	54.91M	54.91M	54.91M	64.42M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.63M	10.29M	5.47M	7.32M	5.51M	12.29M	63.6M	53.22M	16.84M	231.16M
Cash & Short-Term Investments	12.39M	8.97M	3.42M	5.33M	2.39M	9.59M	60.35M	43.76M	9.24M	226.92M
Cash Only	10.14M	5.93M	2.6M	5.33M	2.39M	9.59M	60.35M	20.99M	9.24M	61.58M
Short-Term Investments	2.25M	3.04M	825K	0	0	0	0	22.76M	0	165.34M
Accounts Receivable	604.98K	726K	1.19M	1.15M	2.04M	1.74M	1.65M	1.36M	1.18M	116K
Days Sales Outstanding	46.3	55.66	73.46	57.59	77.07	63.1	55.69	70.03	299.08	-
Inventory	334.39K	323K	516K	530K	645K	665K	1.07M	1.41M	0	0
Days Inventory Outstanding	26.3	30.05	46.15	45.34	51.67	49.21	63.09	94.02	-	-
Other Current Assets	26.69K	271K	335K	305K	426K	301K	535K	6.69M	5.35M	4.13M
Total Non-Current Assets+	4.47M	1.98M	1.99M	2.11M	3.19M	3.22M	3.65M	2.3M	81.05M	109.94M
Property, Plant & Equipment	576.69K	1.05M	1.31M	1.61M	2.74M	2.72M	2.62M	2.06M	6.32M	59.54M
Fixed Asset Turnover	8.27x	4.52x	4.52x	4.55x	3.54x	3.69x	4.13x	3.45x	0.23x	-
Goodwill	0	0	0	0	0	0	0	0	24.06M	0
Intangible Assets	150.53K	230K	198K	162K	138K	130K	107K	86K	50.35M	50M
Long-Term Investments	2.97M	0	0	181K	181K	0	0	150K	133K	0
Other Non-Current Assets	772.04K	694K	478K	155K	137K	373K	926K	-2.3M	182K	405K
Total Assets+	18.1M	12.27M	7.46M	9.42M	8.7M	15.51M	67.25M	58.09M	97.89M	341.1M
Asset Turnover	0.26x	0.39x	0.79x	0.78x	1.11x	0.65x	0.16x	0.12x	0.01x	-
Asset Growth %	-0.21%	-0.32%	-0.39%	0.26%	-0.08%	0.78%	3.34%	-0.14%	0.69%	2.48%
Total Current Liabilities+	1.09M	1.11M	1.83M	1.12M	1.57M	1.33M	1.84M	2.68M	15.66M	18.23M
Accounts Payable	612K	630K	1.39M	683K	654K	494K	847K	1.54M	6.91M	10.34M
Days Payables Outstanding	48.14	58.62	124.41	58.42	52.39	36.56	50.03	102.83	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	49K	52K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	111K	138K	175K	142K	204K	218K	259K	-406K	4.73M	5.48M
Current Ratio	12.47x	9.30x	2.98x	6.53x	3.50x	9.21x	34.47x	19.89x	1.07x	12.68x
Quick Ratio	12.16x	9.01x	2.70x	6.05x	3.09x	8.71x	33.89x	19.36x	1.07x	12.68x
Cash Conversion Cycle	24.46	27.09	-4.8	44.5	76.35	75.76	68.74	61.22	-	-
Total Non-Current Liabilities+	607.48K	561K	590K	621K	1.4M	1.41M	1.02M	0	7.05M	32.2M
Long-Term Debt	0	0	0	0	0	0	0	0	1.68M	1.63M
Capital Lease Obligations	0	0	0	0	769K	652K	392K	0	780K	1.43M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	4.59M	2.5M
Other Non-Current Liabilities	607K	561K	590K	621K	632K	753K	624K	0	0	55K
Total Liabilities	1.7M	1.67M	2.42M	1.74M	2.98M	2.74M	2.86M	3.45M	22.71M	50.43M
Total Debt+	0	0	0	0	1M	897K	652K	0	2.55M	4.06M
Net Debt	-10.14M	-5.93M	-2.6M	-5.33M	-1.39M	-8.69M	-59.7M	-20.99M	-6.69M	-57.52M
Debt / Equity	-	-	-	-	0.18x	0.07x	0.01x	-	0.03x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.39x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-5.50x
Interest Coverage	-5082.00x	-	-	-	-	-	-62.11x	-	-487.39x	-
Total Equity+	16.4M	10.6M	5.03M	7.68M	5.72M	12.77M	64.39M	54.64M	75.18M	290.67M
Equity Growth %	-0.21%	-0.35%	-0.53%	0.53%	-0.25%	1.23%	4.04%	-0.15%	0.38%	2.87%
Book Value per Share	0.30	0.19	0.09	0.11	0.08	0.23	1.17	1.00	1.37	4.51
Total Shareholders' Equity	16.4M	10.6M	5.03M	7.68M	5.72M	12.77M	64.39M	54.64M	75.18M	290.67M
Common Stock	55.01K	55K	56K	67K	69K	87K	142K	142K	282K	70K
Retained Earnings	-66.44M	-72.6M	-79.35M	-84.49M	-87.94M	-89.52M	-95.17M	-105.93M	-152.44M	-231.72M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	-7.54M	-7.59M	-7.67M	0	0	0	0	0	0	-51K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.88M	-5.71M	-5.71M	-5.05M	-3.64M	-2.84M	-7.71M	-12.17M	-36.91M	-18.29M
Operating CF Margin %	-0.81%	-1.2%	-0.96%	-0.69%	-0.38%	-0.28%	-0.71%	-1.71%	-25.74%	-
Operating CF Growth %	-0.1%	-0.47%	0%	0.12%	0.28%	0.22%	-1.72%	-0.58%	-2.03%	0.5%
Net Income	-4.71M	-6.16M	-6.7M	-5.14M	-3.45M	-3.39M	-7.27M	-14.67M	-46.51M	-79.28M
Depreciation & Amortization	470.85K	68K	80K	136K	147K	149K	248K	344K	946K	2.31M
Stock-Based Compensation	290.31K	372K	607K	420K	495K	386K	1.09M	1.34M	3.74M	5.39M
Deferred Taxes	-75.29K	-33K	0	-24K	0	10K	0	-1.68M	-2.65M	-2.1M
Other Non-Cash Items	-260.33K	26K	79K	81K	-2K	72K	77K	472K	5.27M	55.39M
Working Capital Changes	401.26K	17K	222K	-518K	-835K	-67K	-1.85M	338K	2.3M	0
Change in Receivables	444.17K	-184K	-466K	38K	-890K	31K	405K	490K	-426K	1.05M
Change in Inventory	-23.4K	89K	23K	128K	-97K	-274K	-2.67M	-152K	359K	11K
Change in Payables	112.33K	18K	761K	-708K	-29K	76K	236K	0	1.58M	1.89M
Cash from Investing+	8.76M	1.51M	1.86M	401K	-287K	-410K	-284K	-57.68M	24.37M	-218.93M
Capital Expenditures	-491.75K	-549K	-337K	-444K	-273K	-381K	-266K	-302K	-1.07M	-54.41M
CapEx % of Revenue	0.1%	0.12%	0.06%	0.06%	0.03%	0.04%	0.02%	0.04%	0.75%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	12.38K	-124K	-18K	-14K	-14K	-30K	-18K	-57.38M	-18K	78.99M
Cash from Financing+	39.31K	-9K	521K	7.37M	994K	64.68M	56K	56K	785K	289.38M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-10.63K	-11K	-11K	-11K	-11K	-9K	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	56K	489K	289.38M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.38M	-6.26M	-6.05M	-5.49M	-3.91M	-3.22M	-7.98M	-12.47M	-37.98M	-72.71M
FCF Margin %	-0.92%	-1.32%	-1.02%	-0.75%	-0.4%	-0.32%	-0.74%	-1.76%	-26.49%	-
FCF Growth %	-0.19%	-0.43%	0.03%	0.09%	0.29%	0.18%	-1.48%	-0.56%	-2.05%	-0.91%
FCF per Share	-0.08	-0.11	-0.11	-0.08	-0.06	-0.06	-0.15	-0.23	-0.69	-1.13
FCF Conversion (FCF/Net Income)	0.82x	0.93x	0.85x	1.04x	1.11x	0.89x	1.08x	0.83x	0.79x	0.23x
Interest Paid	-	-	-	-	-	-	-	-	84K	0
Taxes Paid	-	-	-	-	-	-	-	-	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-25.34%	-45.64%	-85.72%	-76.32%	-48.78%	-34.47%	-18.54%	-24.65%	-71.65%	-43.34%
Return on Invested Capital (ROIC)	-34.94%	-86.54%	-142.16%	-165.49%	-77.94%	-61.22%	-126.36%	-59.4%	-60.12%	5.2%
Gross Margin	2.71%	17.6%	31.1%	41.66%	52.93%	50.94%	42.76%	23%	100%	-
Net Margin	-98.77%	-129.43%	-113.12%	-66.31%	-33.77%	-31.71%	-66.26%	-206.5%	-3243.24%	-
Debt / Equity	-	-	-	-	0.18x	0.07x	0.01x	-	0.03x	0.01x
Interest Coverage	-5082.00x	-	-	-	-	-	-62.11x	-	-487.39x	-
FCF Conversion	0.82x	0.93x	0.85x	1.04x	1.11x	0.89x	1.08x	0.83x	0.79x	0.23x
Revenue Growth	3.53%	-0.17%	24.41%	23.48%	32.35%	3.85%	7.38%	-34.19%	-79.81%	-100%

Frequently Asked Questions

Growth & Financials

Perspective Therapeutics, Inc. (CATX) reported $0.6M in revenue for fiscal year 2024. This represents a 89% decrease from $5.1M in 2011.

Perspective Therapeutics, Inc. (CATX) saw revenue decline by 100.0% over the past year.

Perspective Therapeutics, Inc. (CATX) reported a net loss of $113.6M for fiscal year 2024.

Dividend & Returns

Perspective Therapeutics, Inc. (CATX) has a return on equity (ROE) of -43.3%. Negative ROE indicates the company is unprofitable.

Perspective Therapeutics, Inc. (CATX) had negative free cash flow of $112.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Perspective Therapeutics, Inc. (CATX) 10-Year Financial Performance & Capital Metrics

CATX • • Industrial / General

HealthcareMedical DevicesOncology & Cancer Treatment DevicesRadiation Therapy Systems

Revenue $0 -100.0%
EBITDA $10M +126.2%
Net Income -$79M -70.5%
EPS (Diluted) -1.23 -44.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -43.34% +39.5%
ROIC 5.2% +108.7%
Debt/Equity 0.01 -58.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 17.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-74.35%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-92.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM-49.38%

ROCE

10Y Avg-40.23%

5Y Avg-26.06%

3Y Avg-26.49%

Latest5.16%

Peer Comparison

Radiation Therapy Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
SRTSSensus Healthcare, Inc.	81.47M	4.96	12.10	71.31%	-8.44%	-5.87%	0.01
CATXPerspective Therapeutics, Inc.	184.36M	2.48	-2.02	-100%	-197.29%	-42.77%	0.01
TLSITriSalus Life Sciences, Inc.	307.28M	6.15	-4.92	58.99%	-98.45%
PROFProfound Medical Corp.	302.68M	8.34	-7.79	41.23%	-272.77%	-130.59%	0.08
DCTHDelcath Systems, Inc.	354.29M	10.21	-11.03	17.02%	1.5%	1.04%	0.02
PTHLPheton Holdings Ltd Class A Ordinary Shares	8.46M	0.90	-17.38	-28.7%	-91.16%	-13.91%	0.04
ARAYAccuray Incorporated	98.61M	0.87	-56.13	2.68%	-4.28%	-31.22%	2.17

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.77M	4.76M	5.92M	7.31M	9.68M	10.05M	10.79M	7.1M	1.43M	0
Revenue Growth %	0.04%	-0%	0.24%	0.23%	0.32%	0.04%	0.07%	-0.34%	-0.8%	-1%
Cost of Goods Sold+	4.64M	3.92M	4.08M	4.27M	4.56M	4.93M	6.18M	5.47M	0	0
COGS % of Revenue	0.97%	0.82%	0.69%	0.58%	0.47%	0.49%	0.57%	0.77%	-	-
Gross Profit+	129.15K	838K	1.84M	3.05M	5.12M	5.12M	4.62M	1.63M	1.43M	0
Gross Margin %	0.03%	0.18%	0.31%	0.42%	0.53%	0.51%	0.43%	0.23%	1%	-
Gross Profit Growth %	-0.23%	5.49%	1.2%	0.65%	0.68%	-0%	-0.1%	-0.65%	-0.12%	-1%
Operating Expenses+	5.21M	7.14M	8.57M	8.32M	8.6M	8.56M	12.01M	17.43M	42.38M	92.34M
OpEx % of Revenue	1.09%	1.5%	1.45%	1.14%	0.89%	0.85%	1.11%	2.45%	29.55%	-
Selling, General & Admin	5.14M	6.23M	6.83M	6.85M	7.55M	7.13M	9.43M	14.21M	21.06M	26.61M
SG&A % of Revenue	1.08%	1.31%	1.15%	0.94%	0.78%	0.71%	0.87%	2%	14.69%	-
Research & Development	528.05K	965K	1.75M	1.47M	1.13M	1.43M	2.58M	2.6M	21.31M	41.64M
R&D % of Revenue	0.11%	0.2%	0.29%	0.2%	0.12%	0.14%	0.24%	0.37%	14.86%	-
Other Operating Expenses	-456.28K	-48K	0	2K	-73K	0	0	0	0	24.09M
Operating Income+	-5.08M	-6.31M	-6.73M	-5.28M	-3.48M	-3.44M	-7.39M	-15.18M	-40.94M	10.46M
Operating Margin %	-1.07%	-1.32%	-1.14%	-0.72%	-0.36%	-0.34%	-0.68%	-2.14%	-28.55%	-
Operating Income Growth %	-0.17%	-0.24%	-0.07%	0.22%	0.34%	0.01%	-1.15%	-1.05%	-1.7%	1.26%
EBITDA+	-4.61M	-6.24M	-6.65M	-5.3M	-3.33M	-3.43M	-7.14M	-14.84M	-39.96M	10.46M
EBITDA Margin %	-0.97%	-1.31%	-1.12%	-0.72%	-0.34%	-0.34%	-0.66%	-2.09%	-27.87%	-
EBITDA Growth %	-0.23%	-0.35%	-0.07%	0.2%	0.37%	-0.03%	-1.08%	-1.08%	-1.69%	1.26%
D&A (Non-Cash Add-back)	470.85K	68K	80K	-24K	147K	9K	248K	344K	981K	0
EBIT	0	-6.31M	-6.73M	-5.28M	0	-3.44M	0	-15.18M	-40.94M	-81.42M
Net Interest Income+	217K	118K	29K	108K	30K	59K	0	1.12M	850K	10.56M
Interest Income	218K	118K	29K	108K	30K	59K	119K	1.12M	934K	10.52M
Interest Expense	1K	0	0	0	0	0	119K	0	84K	-48K
Other Income/Expense	154K	27K	29K	134K	30K	50K	119K	512K	835K	-91.83M
Pretax Income+	-4.71M	-6.16M	-6.7M	-5.14M	-3.45M	-3.39M	-7.27M	-14.67M	-40.11M	-81.38M
Pretax Margin %	-0.99%	-1.29%	-1.13%	-0.7%	-0.36%	-0.34%	-0.67%	-2.07%	-27.97%	-
Income Tax+	-371.19K	-145K	-29K	-294K	-177K	-199K	-119K	0	-2.65M	-2.1M
Effective Tax Rate %	1%	1%	1%	0.94%	0.95%	0.94%	0.98%	1%	1.16%	0.97%
Net Income+	-4.71M	-6.16M	-6.7M	-4.85M	-3.27M	-3.19M	-7.15M	-14.67M	-46.51M	-79.28M
Net Margin %	-0.99%	-1.29%	-1.13%	-0.66%	-0.34%	-0.32%	-0.66%	-2.07%	-32.43%	-
Net Income Growth %	-0.28%	-0.31%	-0.09%	0.28%	0.33%	0.02%	-1.24%	-1.05%	-2.17%	-0.7%
Net Income (Continuing)	-	-	-	-4.85M	-3.27M	-3.19M	-7.15M	-14.67M	-37.45M	-80.43M
Discontinued Operations	0	0	0	0	0	0	0	0	-9.05M	-949K
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.09	-0.11	-0.12	-0.07	-0.05	-0.06	-0.13	-0.27	-0.85	-1.23
EPS Growth %	-0.28%	-0.29%	-0.09%	0.4%	0.33%	-0.2%	-1.24%	-1.08%	-2.15%	-0.45%
EPS (Basic)	-0.09	-0.11	-0.12	-0.07	-0.05	-0.06	-0.13	-0.27	-0.85	-1.23
Diluted Shares Outstanding	55.02M	55.02M	55.16M	67.04M	67.6M	54.91M	54.91M	54.91M	54.91M	64.42M
Basic Shares Outstanding	55.01M	55.02M	55.16M	67.04M	67.6M	54.91M	54.91M	54.91M	54.91M	64.42M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.63M	10.29M	5.47M	7.32M	5.51M	12.29M	63.6M	53.22M	16.84M	231.16M
Cash & Short-Term Investments	12.39M	8.97M	3.42M	5.33M	2.39M	9.59M	60.35M	43.76M	9.24M	226.92M
Cash Only	10.14M	5.93M	2.6M	5.33M	2.39M	9.59M	60.35M	20.99M	9.24M	61.58M
Short-Term Investments	2.25M	3.04M	825K	0	0	0	0	22.76M	0	165.34M
Accounts Receivable	604.98K	726K	1.19M	1.15M	2.04M	1.74M	1.65M	1.36M	1.18M	116K
Days Sales Outstanding	46.3	55.66	73.46	57.59	77.07	63.1	55.69	70.03	299.08	-
Inventory	334.39K	323K	516K	530K	645K	665K	1.07M	1.41M	0	0
Days Inventory Outstanding	26.3	30.05	46.15	45.34	51.67	49.21	63.09	94.02	-	-
Other Current Assets	26.69K	271K	335K	305K	426K	301K	535K	6.69M	5.35M	4.13M
Total Non-Current Assets+	4.47M	1.98M	1.99M	2.11M	3.19M	3.22M	3.65M	2.3M	81.05M	109.94M
Property, Plant & Equipment	576.69K	1.05M	1.31M	1.61M	2.74M	2.72M	2.62M	2.06M	6.32M	59.54M
Fixed Asset Turnover	8.27x	4.52x	4.52x	4.55x	3.54x	3.69x	4.13x	3.45x	0.23x	-
Goodwill	0	0	0	0	0	0	0	0	24.06M	0
Intangible Assets	150.53K	230K	198K	162K	138K	130K	107K	86K	50.35M	50M
Long-Term Investments	2.97M	0	0	181K	181K	0	0	150K	133K	0
Other Non-Current Assets	772.04K	694K	478K	155K	137K	373K	926K	-2.3M	182K	405K
Total Assets+	18.1M	12.27M	7.46M	9.42M	8.7M	15.51M	67.25M	58.09M	97.89M	341.1M
Asset Turnover	0.26x	0.39x	0.79x	0.78x	1.11x	0.65x	0.16x	0.12x	0.01x	-
Asset Growth %	-0.21%	-0.32%	-0.39%	0.26%	-0.08%	0.78%	3.34%	-0.14%	0.69%	2.48%
Total Current Liabilities+	1.09M	1.11M	1.83M	1.12M	1.57M	1.33M	1.84M	2.68M	15.66M	18.23M
Accounts Payable	612K	630K	1.39M	683K	654K	494K	847K	1.54M	6.91M	10.34M
Days Payables Outstanding	48.14	58.62	124.41	58.42	52.39	36.56	50.03	102.83	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	49K	52K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	1000K
Other Current Liabilities	111K	138K	175K	142K	204K	218K	259K	-406K	4.73M	5.48M
Current Ratio	12.47x	9.30x	2.98x	6.53x	3.50x	9.21x	34.47x	19.89x	1.07x	12.68x
Quick Ratio	12.16x	9.01x	2.70x	6.05x	3.09x	8.71x	33.89x	19.36x	1.07x	12.68x
Cash Conversion Cycle	24.46	27.09	-4.8	44.5	76.35	75.76	68.74	61.22	-	-
Total Non-Current Liabilities+	607.48K	561K	590K	621K	1.4M	1.41M	1.02M	0	7.05M	32.2M
Long-Term Debt	0	0	0	0	0	0	0	0	1.68M	1.63M
Capital Lease Obligations	0	0	0	0	769K	652K	392K	0	780K	1.43M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	4.59M	2.5M
Other Non-Current Liabilities	607K	561K	590K	621K	632K	753K	624K	0	0	55K
Total Liabilities	1.7M	1.67M	2.42M	1.74M	2.98M	2.74M	2.86M	3.45M	22.71M	50.43M
Total Debt+	0	0	0	0	1M	897K	652K	0	2.55M	4.06M
Net Debt	-10.14M	-5.93M	-2.6M	-5.33M	-1.39M	-8.69M	-59.7M	-20.99M	-6.69M	-57.52M
Debt / Equity	-	-	-	-	0.18x	0.07x	0.01x	-	0.03x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.39x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-5.50x
Interest Coverage	-5082.00x	-	-	-	-	-	-62.11x	-	-487.39x	-
Total Equity+	16.4M	10.6M	5.03M	7.68M	5.72M	12.77M	64.39M	54.64M	75.18M	290.67M
Equity Growth %	-0.21%	-0.35%	-0.53%	0.53%	-0.25%	1.23%	4.04%	-0.15%	0.38%	2.87%
Book Value per Share	0.30	0.19	0.09	0.11	0.08	0.23	1.17	1.00	1.37	4.51
Total Shareholders' Equity	16.4M	10.6M	5.03M	7.68M	5.72M	12.77M	64.39M	54.64M	75.18M	290.67M
Common Stock	55.01K	55K	56K	67K	69K	87K	142K	142K	282K	70K
Retained Earnings	-66.44M	-72.6M	-79.35M	-84.49M	-87.94M	-89.52M	-95.17M	-105.93M	-152.44M	-231.72M
Treasury Stock	-	-	-	-	-	-	-	-	0	0
Accumulated OCI	-7.54M	-7.59M	-7.67M	0	0	0	0	0	0	-51K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.88M	-5.71M	-5.71M	-5.05M	-3.64M	-2.84M	-7.71M	-12.17M	-36.91M	-18.29M
Operating CF Margin %	-0.81%	-1.2%	-0.96%	-0.69%	-0.38%	-0.28%	-0.71%	-1.71%	-25.74%	-
Operating CF Growth %	-0.1%	-0.47%	0%	0.12%	0.28%	0.22%	-1.72%	-0.58%	-2.03%	0.5%
Net Income	-4.71M	-6.16M	-6.7M	-5.14M	-3.45M	-3.39M	-7.27M	-14.67M	-46.51M	-79.28M
Depreciation & Amortization	470.85K	68K	80K	136K	147K	149K	248K	344K	946K	2.31M
Stock-Based Compensation	290.31K	372K	607K	420K	495K	386K	1.09M	1.34M	3.74M	5.39M
Deferred Taxes	-75.29K	-33K	0	-24K	0	10K	0	-1.68M	-2.65M	-2.1M
Other Non-Cash Items	-260.33K	26K	79K	81K	-2K	72K	77K	472K	5.27M	55.39M
Working Capital Changes	401.26K	17K	222K	-518K	-835K	-67K	-1.85M	338K	2.3M	0
Change in Receivables	444.17K	-184K	-466K	38K	-890K	31K	405K	490K	-426K	1.05M
Change in Inventory	-23.4K	89K	23K	128K	-97K	-274K	-2.67M	-152K	359K	11K
Change in Payables	112.33K	18K	761K	-708K	-29K	76K	236K	0	1.58M	1.89M
Cash from Investing+	8.76M	1.51M	1.86M	401K	-287K	-410K	-284K	-57.68M	24.37M	-218.93M
Capital Expenditures	-491.75K	-549K	-337K	-444K	-273K	-381K	-266K	-302K	-1.07M	-54.41M
CapEx % of Revenue	0.1%	0.12%	0.06%	0.06%	0.03%	0.04%	0.02%	0.04%	0.75%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	12.38K	-124K	-18K	-14K	-14K	-30K	-18K	-57.38M	-18K	78.99M
Cash from Financing+	39.31K	-9K	521K	7.37M	994K	64.68M	56K	56K	785K	289.38M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-10.63K	-11K	-11K	-11K	-11K	-9K	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	56K	489K	289.38M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.38M	-6.26M	-6.05M	-5.49M	-3.91M	-3.22M	-7.98M	-12.47M	-37.98M	-72.71M
FCF Margin %	-0.92%	-1.32%	-1.02%	-0.75%	-0.4%	-0.32%	-0.74%	-1.76%	-26.49%	-
FCF Growth %	-0.19%	-0.43%	0.03%	0.09%	0.29%	0.18%	-1.48%	-0.56%	-2.05%	-0.91%
FCF per Share	-0.08	-0.11	-0.11	-0.08	-0.06	-0.06	-0.15	-0.23	-0.69	-1.13
FCF Conversion (FCF/Net Income)	0.82x	0.93x	0.85x	1.04x	1.11x	0.89x	1.08x	0.83x	0.79x	0.23x
Interest Paid	-	-	-	-	-	-	-	-	84K	0
Taxes Paid	-	-	-	-	-	-	-	-	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-25.34%	-45.64%	-85.72%	-76.32%	-48.78%	-34.47%	-18.54%	-24.65%	-71.65%	-43.34%
Return on Invested Capital (ROIC)	-34.94%	-86.54%	-142.16%	-165.49%	-77.94%	-61.22%	-126.36%	-59.4%	-60.12%	5.2%
Gross Margin	2.71%	17.6%	31.1%	41.66%	52.93%	50.94%	42.76%	23%	100%	-
Net Margin	-98.77%	-129.43%	-113.12%	-66.31%	-33.77%	-31.71%	-66.26%	-206.5%	-3243.24%	-
Debt / Equity	-	-	-	-	0.18x	0.07x	0.01x	-	0.03x	0.01x
Interest Coverage	-5082.00x	-	-	-	-	-	-62.11x	-	-487.39x	-
FCF Conversion	0.82x	0.93x	0.85x	1.04x	1.11x	0.89x	1.08x	0.83x	0.79x	0.23x
Revenue Growth	3.53%	-0.17%	24.41%	23.48%	32.35%	3.85%	7.38%	-34.19%	-79.81%	-100%

Frequently Asked Questions

Growth & Financials

Perspective Therapeutics, Inc. (CATX) reported $0.6M in revenue for fiscal year 2024. This represents a 89% decrease from $5.1M in 2011.

Perspective Therapeutics, Inc. (CATX) saw revenue decline by 100.0% over the past year.

Perspective Therapeutics, Inc. (CATX) reported a net loss of $113.6M for fiscal year 2024.

Dividend & Returns

Perspective Therapeutics, Inc. (CATX) has a return on equity (ROE) of -43.3%. Negative ROE indicates the company is unprofitable.

Perspective Therapeutics, Inc. (CATX) had negative free cash flow of $112.4M in fiscal year 2024, likely due to heavy capital investments.